Mark Lanier News
-
Takeda Pharmaceutical Co. persuaded a judge to throw out a $6.5 million jury verdict over its Actos diabetes drug because lawyers for a California man didn’t produce sufficient evidence to show his cancer was caused by the medication.
-
Federal jurors began hearing a contract dispute today over whether Ingersoll Rand Plc owes $11 million or $72 million to 130 employees under an incentive plan tied to its sale of a subsidiary, Dresser-Rand Group Inc.
-
BP Plc faces more than 225 lawsuits in 11 states as litigation from businesses, individuals and investors continues to increase almost two months after the Deepwater Horizon oil rig exploded.
-
A federal appeals court in New Orleans set an expedited hearing date for arguments over whether to lift a moratorium on deep-water drilling. The hearing is scheduled for July 8.
-
Plaintiff lawyers involved in Merck & Co. ’s $4.85 billion Vioxx settlement are accusing some of their colleagues of attempting to hog the lion’s share of more than $315 million in fees spawned by the accord.
-
Roche Holding AG’s Genentech Inc. is facing the first trial of patients’ claims that its withdrawn Raptiva psoriasis drug spawned fatal infections in some users.
-
Roche Holdings AG denied settling lawsuits that say its Raptiva psoriasis drug caused lethal infections and said it’s proceeding to the first trial of the claims in June.
-
About a dozen state attorneys general met last week to discuss their mortgage investigations and how they might work together as settlement talks with banks over foreclosures drag on, three people familiar with the matter said.
-
BP Plc was sued by members of its employee savings plan over losses tied to company’s plunging stock price amid the oil leak disaster in the Gulf of Mexico.
-
Former presidential candidate John Edwards isn’t likely to be retried for using illegal campaign contributions to hide an extramarital affair after a jury acquitted him on one count and failed to reach a verdict on five others, according to a person familiar with the matter.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page